ARTICLE | Company News
RiboGene other research news
October 14, 1996 7:00 AM UTC
RiboGene received a $750,000 Phase II SBIR from the National Institute of Allergy and Infectious Diseases to discover and develop small molecule drugs to treat hepatitis C using its high throughput sc...